BCAB
BioAtla (BCAB)
$84
About BioAtla (BCAB)
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Details
Daily high
$5.18
Daily low
$4.36
Price at open
$4.36
52 Week High
$71.50
52 Week Low
$3.92
Market cap
8.0M
Dividend yield
0.00%
Volume
58,327
Avg. volume
38,138
P/E ratio
-.10
BioAtla News
Details
Daily high
$5.18
Daily low
$4.36
Price at open
$4.36
52 Week High
$71.50
52 Week Low
$3.92
Market cap
8.0M
Dividend yield
0.00%
Volume
58,327
Avg. volume
38,138
P/E ratio
-.10